.svg)
In a recent Ynet News piece, Dr. Yuval Tal, director of the Allergy and Clinical Immunology Unit at Hadassah Hospital Ein Kerem, shares the remarkable story of a patient with multiple myeloma whose debilitating pain and severe itching persisted despite years of treatment.
Most conventional treatments had failed, but Dr. Tal believed there had to be another possibility. "The failure of standard treatments did not mean that all options had been exhausted," he wrote.
Dr. Tal and his team looked for the biological mechanism driving the patient's symptoms. That led Dr. Tal to recommend omalizumab, an antibody therapy typically used to treat severe allergies and asthma. Within weeks of receiving three injections, the patient's pain and itching improved dramatically, allowing him to stop taking many of his pain medications and regain his quality of life.
The treatment changed everything for the patient. Before coming to Hadassah Ein Kerem, the patient had purchased a ticket to Switzerland to pursue physician-assisted euthanasia. After the successful Hadassah treatment, he tore up the ticket.
“The immune system remains far from fully understood and still holds many mysteries,” wrote Dr. Tal. “But as researchers learn more about how immune cells communicate and how shared mechanisms connect seemingly different diseases, new treatment options continue to emerge, and with them, new reasons for hope.”
